• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Neuropore Therapies appoints Dr. Errol De Souza president and CEO

Neuropore Therapies appoints Dr. Errol De Souza president and CEO

January 23, 2017
CenterWatch Staff

Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, announced that Errol De Souza, Ph.D. has been appointed president and chief executive officer effective immediately.

“Errol is a proven leader in the biopharmaceutical industry. He possesses the experience, business vision and track record that will take Neuropore to the next phase of its growth as we look to advance compounds from our research pipeline into development,” stated Herbert Moessler, chairman of the board of directors at Neuropore.

"I am delighted to have the opportunity to lead Neuropore at this point in the company's transformation," said Dr. De Souza. "With a strong research platform in the exciting areas of autophagy and neuroinflammation and an established collaboration with a major pharmaceutical company with a compound in clinical development, I believe Neuropore has the potential to deliver significant value for patients and shareholders. I look forward to working with Neuropore's executive team and Board to advance the company."

Previous to Errol De Souza’s appointment at Neuropore, he served as president and chief executive officer of several public (Biodel; Synaptic Pharmaceutical) and private (Archemix) biotech companies.

Dr. De Souza has raised hundreds of million dollars in capital in private (venture) and public sectors. Also, he has been involved in taking companies public (Neurocrine Biosciences IPO), executed M&A deals including Synaptic Pharmaceuticals sale to H. Lundbeck, and has served in a number of high-ranking R&D roles, including senior vice president and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and executive vice president of Research and Development at Neurocrine Biosciences (1992-1998), and head of CNS Diseases Research at DuPont Merck (1990 – 1992).

He has extensive board experience and serves or has served on the board of directors of several private companies and public companies.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing